Search results for "progress"

showing 10 items of 1620 documents

Extracellular Matrix Molecular Remodeling in Human Liver Fibrosis Evolution

2016

Chronic liver damage leads to pathological accumulation of ECM proteins (liver fibrosis). Comprehensive characterization of the human ECM molecular composition is essential for gaining insights into the mechanisms of liver disease. To date, studies of ECM remodeling in human liver diseases have been hampered by the unavailability of purified ECM. Here, we developed a decellularization method to purify ECM scaffolds from human liver tissues. Histological and electron microscopy analyses demonstrated that the ECM scaffolds, devoid of plasma and cellular components, preserved the three-dimensional ECM structure and zonal distribution of ECM components. This method has been then applied on 57 l…

Liver Cirrhosis0301 basic medicineProteomicsPathologyProteomeBiopsylcsh:MedicineHepacivirusMatrix (biology)ProteomicsBiochemistryExtracellular matrixMiceLiver disease0302 clinical medicineFibrosisSettore BIO/13 - Biologia ApplicataMedicine and Health Scienceslcsh:Scienceliver fibrosisExtracellular Matrix ProteinsMultidisciplinaryDecellularizationAnimals; Extracellular Matrix; Hepacivirus; Humans; Liver; Liver Cirrhosis; Mice; Proteome; Proteomics; Tissue Scaffolds; Disease ProgressionTissue ScaffoldsChemistryLiver DiseasesLiver030220 oncology & carcinogenesisProteomeDisease ProgressionCellular Structures and OrganellesAnatomyliver fibrosis; extracellular matrix; proteomicsResearch Articlemedicine.medical_specialtyHistologySettore BIO/06extracellular matrixSurgical and Invasive Medical ProceduresGastroenterology and HepatologyScaffold03 medical and health sciencesmedicineAnimalsHumansHuman liverlcsh:RBiology and Life SciencesProteinsCell Biologymedicine.diseaseFibrosisLiver Fibrosi030104 developmental biologyLiver Fibrosis; Scaffold; Proteomicslcsh:QCollagensDevelopmental Biology
researchProduct

New clinical and pathophysiological perspectives defining the trajectory of cirrhosis

2021

Traditionally, the complications of cirrhosis, namely variceal bleeding, ascites and hepatic encephalopathy, were thought to result predominantly from circulatory dysfunction and altered organ perfusion arising as a result of portal hypertension. Over the past 20 years, large, international prospective studies have indicated the importance of systemic inflammation and organ immunopathology as additional determinants of organ dysfunction in cirrhosis, which not only manifests in the liver, brain, circulation and the kidneys, but also the immune system, gut, muscles, adrenal glands, reproductive organs, heart and lungs. This review provides an overview of the traditional and emerging concepts…

Liver Cirrhosis0301 basic medicinemedicine.medical_specialtyVaricesCirrhosisSystemic inflammationImmune System Phenomena03 medical and health sciences0302 clinical medicineImmunopathologyAscitesmedicineAcute on chronic liver failureHumansDecompensationIntensive care medicineHepatic encephalopathyHepatic encephalopathyInflammationHepatologybusiness.industryResearchOrgan dysfunctionGastroenterologyAscitesAcute on chronic liver failure; Ascites; Cirrhosis; Hepatic encephalopathy; Infection; Inflammation; Varicesmedicine.disease030104 developmental biologyCirrhosisDisease ProgressionPortal hypertension030211 gastroenterology & hepatologymedicine.symptombusinessInfection
researchProduct

Chronic hepatitis B in Italy: New features of an old disease - Approaching the universal prevalence of hepatitis B e antigen-negative cases and the e…

2008

We evaluated 1336 hepatitis B surface antigen-positive subjects consecutively observed in 79 Italian hospitals over a 6-month period. The proportion of hepatitis B e antigen-negative cases was 86.4%, that of patients coinfected with hepatitis D virus was 9.7%, and the rate of patients coinfected with hepatitis C virus was 16.8%. Multiple logistic regression analysis showed that age >49 years, alcohol abuse, and anti-hepatitis D virus and anti-hepatitis C virus positivity were independent predictors of progression to liver cirrhosis. © 2007 by the Infectious Diseases Society of America. All rights reserved.

Liver CirrhosisAdultMaleMicrobiology (medical)medicine.medical_specialtyCirrhosisAdolescentHepatitis D ChronicHepatitis C virusHepacivirusLiver CirrhosiHepacivirusmedicine.disease_causeGastroenterologyVirusFlaviviridaeHepatitis B ChronicSeroepidemiologic StudiesInternal medicinemedicineHumansHepatitis B e AntigensAgedAged 80 and overCross-Sectional StudieHepacivirubiologybusiness.industrySeroepidemiologic StudieHepatitis Delta ViruHepatitis BMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis DVirologyAlcoholismCross-Sectional StudiesInfectious DiseasesItalyDisease ProgressionFemaleHepatitis B e AntigenHepatitis D virusHepatitis Delta VirusbusinessHuman
researchProduct

Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease

2017

Background: Sarcopenia recognises insulin resistance and obesity as risk factors, and is frequently associated with cardiometabolic disorders, including non-alcoholic fatty liver disease (NAFLD). Aim: To test the prevalence of sarcopenia and its relation with the severity of fibrosis (main outcome) and the entire spectrum of liver histology in patients with NAFLD. Methods: We considered 225 consecutive patients with histological diagnosis of NAFLD (Kleiner score). The skeletal muscle index (%) (total appendicular skeletal muscle mass (kg)/weight (kg) × 100), a validated measure of sarcopenia, was assessed by bioelectrical impedance analysis. Sarcopenia was defined as a skeletal muscle mass…

Liver CirrhosisAdultMaleSarcopeniamedicine.medical_specialtyLiver CirrhosiSeverity of Illness IndexGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineInsulin resistanceRisk FactorsNon-alcoholic Fatty Liver DiseaseFibrosisInternal medicineDiabetes mellitusSeverity of illnessmedicineHumansPharmacology (medical)Prospective StudiesObesityAgedCross-Sectional StudieHepatologybusiness.industryRisk FactorFatty liverGastroenterologyMiddle Agedmusculoskeletal systemmedicine.diseaseProspective StudieCross-Sectional StudiesEndocrinology030220 oncology & carcinogenesisSarcopeniaDisease ProgressionFemale030211 gastroenterology & hepatologyInsulin ResistanceSteatosisbusinesshuman activitiesHumanAlimentary Pharmacology & Therapeutics
researchProduct

Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C.

2014

BACKGROUND & AIMS: Fibrogenesis results in release of certain extracellular matrix protein fragments into the circulation. We evaluated the diagnostic and prognostic performance of two novel serological markers, the precisely cleaved N-terminal propeptide of type III collagen (Pro-C3) and a peptide of helical collagen type III degradation (C3M), in chronic hepatitis C (CHC) patients. METHOD: Pro-C3 and C3M were measured by ELISA in plasma from CHC patients (n = 194) from a prior phase II antifibrotic trial (NCT00244751). Plasma samples and paired liver biopsies were obtained at baseline and after 1-year. Patients were stratified according to Ishak stages 2-4. Internal cross-validation w…

Liver CirrhosisCollagen Type III/bloodPathologymedicine.medical_specialtyLiver fibrosisEnzyme-Linked Immunosorbent AssayGastroenterologySerologyExtracellular matrixCohort StudiesCollagen Type IIIFibrosisPredictive Value of TestsInternal medicinemedicineHumansStage (cooking)Hepatologybusiness.industryFibroTestBiomarkerHepatitis C ChronicPrognosismedicine.diseaseCollagen Type IIIPredictive value of testsMultivariate AnalysisExtracellular matrix remodellingDisease ProgressionBiomarker (medicine)Hepatitis C Chronic/bloodbusinessLiver Cirrhosis/diagnosisBiomarkers/bloodBiomarkersLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Dendritic cells in liver injury and fibrosis: shortcomings and promises.

2013

SummaryThe phenotype and function of liver dendritic cells (LDCs) are poorly understood. This Snapshot summarizes our current knowledge on LDCs in the healthy and injured liver, and their role in fibrosis progression and reversal. It also draws attention to various pitfalls in the current experimental design and conclusions based on available data.

Liver CirrhosisLiver dendritic cellsPlasmacytoid dendritic cellBiologyCCL2MiceFMS-like tyrosine kinase 3 ligandFibrosismedicineAnimalsHumansAntigen-presenting cellLiver injuryHepatologyFlt3LDendritic Cellsmedicine.diseaseCD11c-DTRDisease Models Animalmedicine.anatomical_structurePhenotypeLiverImmunologyHepatic stellate cellDisease ProgressionBone marrowToleranceJournal of hepatology
researchProduct

GDF11 induces mild hepatic fibrosis independent of metabolic health

2020

BACKGROUND & AIMS: Growth Differentiation Factor 11 (GDF11) is an anti-aging factor, yet its role in liver diseases is not established. We evaluated the role of GDF11 in healthy conditions and in the transition from non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH). RESULTS: GDF11 mRNA levels positively correlated with NAFLD activity score and with CPT1, SREBP, PPAR? and Col1A1 mRNA levels, and associated to portal fibrosis, in morbidly obese patients with NAFLD/NASH. GDF11-treated mice showed mildly exacerbated hepatic collagen deposition, accompanied by weight loss and without changes in liver steatosis or inflammation. GDF11 triggered ALK5-dependent SMAD2/…

Liver CirrhosisMaleAgingSettore MED/09 - Medicina Interna*liverLiver Cirrhosis ExperimentalFetgeWeight lossFibrosisfibrosis; growth differentiation factor 11; liver; NAFLD; NASHNon-alcoholic Fatty Liver DiseaseGrowth differentiation factor 11Fatty liverNASH*fibrosisMiddle AgedObesity MorbidGrowth Differentiation FactorsLiverBone Morphogenetic ProteinsDisease ProgressionFemalemedicine.symptomResearch PaperSignal TransductionAdultmedicine.medical_specialtygrowth differentiation factor 11Inflammationliverdigestive systemCell LineEnvellimentInternal medicineNAFLDmedicineHepatic Stellate CellsAnimalsHumansddc:612*growth differentiation factor 11business.industry*NAFLDfibrosisnutritional and metabolic diseasesCell Biologyliver NAFLD NASH fibrosis growth differentiation factor 11*NASHmedicine.diseaseFibrosisdigestive system diseasesMice Inbred C57BLEndocrinologyPortal fibrosisCase-Control StudiesGDF11Hepatic stellate cellSteatohepatitisHepatic fibrosisbusiness
researchProduct

Genetic similarity of hepatitis C virus and fibrosis progression in chronic and recurrent infection after liver transplantation

2006

SUMMARY. The effect of hepatitis C virus (HCV) genetic heterogeneity on clinical features of post-transplantation hepatitis C is controversial. Different regions of the HCV genome have been associated with apoptosis, fibrosis, and other pathways leading to liver damage in chronic HCV infection. Besides, differences in immunodominant regions, such as NS3, may influence HCV-specific immune responses and disease outcome. In the liver transplant setting, a recent study has reported a positive association between HCV-1b Core region genetic relatedness 5-year post-transplantation and histological severity of recurrent hepatitis C. We have compared nucleotide sequences of HCV Core, NS3 and NS5b re…

Liver CirrhosisMaleCirrhosisBiopsyHepatitis C virusmedicine.medical_treatmentGenome ViralHepacivirusViral Nonstructural ProteinsLiver transplantationBiologymedicine.disease_causeVirusCohort StudiesSpecies SpecificityRecurrenceFibrosisVirologymedicineHumansHepatologySequence Analysis RNAGenetic heterogeneityViral Core Proteinsvirus diseasesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseasedigestive system diseasesLiver TransplantationChronic infectionInfectious DiseasesLiverSpainImmunologyDisease ProgressionFemaleJournal of Viral Hepatitis
researchProduct

Competing risks and prognostic stages of cirrhosis: A 25-year inception cohort study of 494 patients

2014

Summary Background Morphological, haemodynamic and clinical stages of cirrhosis have been proposed, although no definite staging system is yet accepted for clinical practice. Aim To investigate whether clinical complications of cirrhosis may define different prognostic disease stages. Methods Analysis of the database from a prospective inception cohort of 494 patients. Decompensation was defined by ascites, bleeding, jaundice or encephalopathy. Explored potential prognostic stages: 1, compensated cirrhosis without oesophago-gastric varices; 2, compensated cirrhosis with varices; 3, bleeding without other complications; 4, first nonbleeding decompensation; 5, any second decompensating event.…

Liver CirrhosisMaleCirrhosisSettore MED/09 - Medicina InternaDatabases Factualmedicine.medical_treatmentLiver transplantationGastroenterologyCohort StudiesModel for End-Stage Liver DiseaseAscitesEsophageal and Gastric VariceMedicinePharmacology (medical)Prospective StudiesProspective cohort studyLiver NeoplasmsGastroenterologyAscitesJaundiceMiddle AgedPrognosisLiver NeoplasmAsciteDisease ProgressionFemalemedicine.symptomHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularPrognosiLiver CirrhosiJaundiceEsophageal and Gastric VaricesRisk AssessmentFollow-Up StudieInternal medicineHumansDecompensationAgedHepatologybusiness.industrymedicine.diseaseLiver TransplantationProspective StudieCohort StudiebusinessVaricesFollow-Up Studies
researchProduct

Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals

2018

Background: Despite the dramatic improvement in viral eradication rates that has been reached with direct antiviral agents (DAAs),the real benefit of viral eradication after DAAs on hepatocellular carcinoma (HCC) development is still controversial. Aim: To prospectively assess the risk of HCC occurrence and early recurrence in a large cohort of DAAtreated HCV-cirrhotic patients and to identify potential predictors of HCC development. Methods: We analyzed data prospectively collected from 1927 consecutive HCV-infected cirrhotic patients treated with DAA from January to December 2015 in 10 tertiary liver centers in Italy and followed-up for one year after therapy. 161 patients had a previous …

Liver CirrhosisMaleCirrhosisSustained Virologic ResponseHepatocellular carcinomaDirect antiviral agentsDIRECT ACTING ANTIVIRALSGastroenterologyCohort Studies0302 clinical medicineRisk FactorsChronicIncidence (epidemiology)Liver NeoplasmsGastroenterologyMiddle AgedHepatitis CTumor recurrenceCirrhosis; Direct antiviral agents; HCV; Hepatocellular carcinoma; Aged; Antiviral Agents; Carcinoma Hepatocellular; Cohort Studies; Disease Progression; Female; Hepatitis C Chronic; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Risk Factors; alpha-Fetoproteins; Sustained Virologic ResponseItalyLocalCirrhosis030220 oncology & carcinogenesisHepatocellular carcinomaHCVDisease ProgressionPortal hypertension030211 gastroenterology & hepatologyFemalealpha-FetoproteinsCohort studymedicine.medical_specialtyCarcinoma HepatocellularEarly RecurrenceAntiviral Agents03 medical and health sciencesInternal medicinemedicineHumansneoplasmsAgedCirrhosiHepatologybusiness.industryCarcinomaHepatocellularHepatitis C Chronicmedicine.diseasedigestive system diseasesNeoplasm RecurrenceDirect antiviral agentNeoplasm Recurrence LocalCirrhosis; Direct antiviral agents; HCV; Hepatocellular carcinomabusiness
researchProduct